巴基斯坦的药品短缺更加恶化,因为推迟的价格批准阻碍合法获得关键药物,危及病人的护理。 Pakistan's medicine shortage worsens as delayed price approvals block legal access to vital drugs, endangering patient care.

巴基斯坦面临包括癌症治疗、疫苗和慢性病药物在内的基本药品严重短缺的问题,原因是尽管巴基斯坦药品管理局已最后确定定价建议,但政府迟迟不能核准药品价格。 Pakistan faces a severe shortage of essential medicines, including cancer treatments, vaccines, and drugs for chronic diseases, due to delays in government approval of drug prices, despite the Drug Regulatory Authority of Pakistan having finalized pricing recommendations. 虽然从中国进口药品仍然正常,但制药公司在没有正式价格通知的情况下不能合法进口或分发新批准的药品,从而造成监管瓶颈。 Although imports from China continue normally, pharmaceutical companies cannot legally import or distribute newly approved medicines without official price notifications, creating a regulatory bottleneck. 这扰乱了全国范围获得救生治疗的机会,使人们对病人转向不安全、无管制或假冒的替代品感到关切。 This has disrupted access to life-saving treatments nationwide, raising concerns about patients turning to unsafe, unregulated, or counterfeit alternatives. 专家警告这次危机暴露了医疗保健治理方面的系统性弱点,并威胁到公共健康。 Experts warn the crisis exposes systemic weaknesses in healthcare governance and threatens public health.